Mineralys Therapeutics (MLYS) financial statements
Net income was -$155M.
Free cash flow was -$142M.
The diluted share count rose 1209% over the period (dilution).
Income statement
Fiscal years, from Mineralys Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Research and development | $26M | $70M | $169M | $132M |
| Selling, general and admin | $5M | $14M | $24M | $39M |
| Operating income | -$31M | -$85M | -$192M | -$171M |
| Income tax | — | — | — | $0 |
| Net income | -$30M | -$72M | -$178M | -$155M |
| EPS (diluted) | -$5.77 | -$1.99 | -$3.66 | -$2.29 |
| Diluted shares | 5M | 36M | 49M | 68M |
Balance sheet
Fiscal years, from Mineralys Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $88M | $49M | $114M | $173M |
| Total current assets | $113M | $249M | $205M | $661M |
| Property, plant and equipment | — | $0 | $53,000 | $38,000 |
| Total assets | $114M | $252M | $206M | $662M |
| Total current liabilities | $8M | $10M | $15M | $15M |
| Total liabilities | $167M | $10M | $15M | $15M |
| Shareholders' equity | -$52M | $241M | $191M | $647M |
| Net debt | -$88M | -$49M | -$114M | -$173M |
Cash flow
Fiscal years, from Mineralys Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -$29M | -$81M | -$166M | -$142M |
| Capital spending | — | $0 | $96,000 | $15,000 |
| Free cash flow | — | -$81M | -$166M | -$142M |
| Stock-based compensation | $455,000 | $5M | $11M | $19M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MLYS.
Open MLYS in InvestinglyQuestions
How much free cash flow does Mineralys Therapeutics generate?
-$142M in fiscal 2025 (operating cash flow minus capital spending).
From Mineralys Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.